Skip to main content

Vertex Value Stock - Dividend - Research Selection

Vertex Pharmaceuticals

ISIN: US92532F1003, WKN: 882807

Market price date: 16.05.2022
Market price: 254,17 USD

Vertex Pharmaceuticals Fundamental data and company key figures of the share

Annual reports in USD
Key figures 10-02-2022
Cash flow
Net operating cash flow 2.643.500.000
Capital Expenditures -235.000.000
Free cash flow 2.408.499.968
Balance sheet
Total Equity
Liabilities & Shareholders equity 13.432.000.000
Income statement
Net income 2.342.000.000
Eps (diluted) 9,018
Diluted shares outstanding 259.707.000
Net sales/revenue 7.574.000.000

Fundamental ratios calculated on: 16-05-2022

Key figures 16-05-2022
Cash flow
P/C 24,97
P/FC 27,41
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization66.009.726.976,00 USD
CountryUnited States
IndicesMSCI World Index,NASDAQ 100,NASDAQ Comp.,S&P 500
Raw Data SourceUS GAAP in Millionen USD
Stock Split2000-08-24,2.0000/1.0000

Description of the company

Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases. The Company's two products are INCIVEK (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus (HCV), infection, and KALYDECO (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis (CF), who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), gene. The Company has ongoing clinical programs involving drug candidates intended for the treatment of HCV infection, CF, rheumatoid arthritis, influenza and epilepsy. INCIVEK (telaprevir) achieved initial commercial acceptance following its approval in May 2011. It started marketing KALYDECO in the United States in January 2012.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey Leiden Center for Cell and Genetic Therapies

-New 344,000 square foot cell and genetic therapies research and manufacturing facility to be built--Facility to support continued R&D growth-... | May 17, 2022

Vertex Announces $50 Million Commitment to Health Equity With Three Initial Grants

– Vertex grant to JDRF supports efforts to improve clinical trial diversity in type 1 diabetes –– The Vertex Foundation grant supports the Mass General Comprehensive Sickle... | May 17, 2022

CRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed Drugs

While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.

Large Cap Biopharmaceuticals: Provide Growth, Value And Yield


Here's the No. 1 Reason to Buy Vertex Pharmaceuticals Now

The company's current treatments dominate the cystic fibrosis market, but it's the pipeline that makes this stock so intriguing.

How to Avoid the Biotech Bear Market: Get Some Products Approved

We find 10 biotech stocks that have returned more than 3% in 2022. All have drugs on the market, which investors seem to like.

Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day

Shares of Vertex Pharmaceuticals Inc. rallied 2.44% to $246.72 Friday, on what proved to be an all-around favorable trading session for the stock market,...

These 5-Stock Samplers Have Gotten Whacked. And That's OK

Our track record with 5-Stock Samplers has been simply astounding. So many times we've crushed the market! But remember when we said it wouldn't always be that way? That to win we sometimes have to lose? This is that time, Fools.

Biotech Stock Roundup: REGN, VRTX Earnings Update, BHVN Up on Regulatory News

Earnings and regulatory updates from Regeneron (REGN) and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.

Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors

Shares of Vertex Pharmaceuticals Inc. slid 2.17% to $234.96 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with...